



Tanoğlu A, San O. Entecavir Induced Severe Myopathy: An Uncommon Side Effect. J Mol Virol Immunol 2021; 2(1): 15-17.

Makale numarası	JMVI-2021-004	Manuscript number	JMVI-2021-004
Ülke / Bölge	Türkiye	Country / Territory	Turkey
Kategori	Viroloji, Enfeksiyon Hastalıkları	Category	Virology, Infectious Diseases
Makale tipi	Olgu Sunumu	Manuscript type	Case Report
Makale dili	İngilizce	Manuscript language	English
Özet ve makale başlığı	İngilizce ve Türkçe	Abstract and article title	English and Turkish
Bu makale çift-kör değerlendirilmeden geçmiştir.		This article peer reviewed by double blind process.	
Makalenin gelişinden yayımlanma tarihine kadar toplam değerlendirme süresi	4 gün	Total evaluation time from the received of the article to the publication date (days)	4 days
Kabul edilen makalenin iThenticate benzerlik oranı (referanslar hariç)	[%9]	iThenticate similarity rate (excluding references)	[9%]
Kabul edilen makalenin ilk hakem değerlendirme puanlarının ortalaması (100 puan üzerinden)	70,0	Average of the reviewer first evaluation scores of the accepted article (out of 100 points)	70
Makale geliş tarihi	3.04.2021	Article received date	3.04.2021
Editör / Alan Editörü	Dr. Fatih ŞAHİNER	Editor / Field Editor	Dr. Fatih ŞAHİNER
Ön inceleme: Değerlendirmeye almak için temel kriterleri taşıyor mu?	Evet	Pre-review: Does it meet the basic criteria for taking the assessment?	Yes
iThenticate benzerlik oranı (ilk inceleme)	-	iThenticate similarity rate (first review)	-

Bu makale için iThenticate benzerlik analizi değerlendirme süreci tamamlandıktan sonra yapılmıştır (belgenin sonraki sayfalarına bakınız)

The iThenticate similarity analysis for this article was performed after the evaluation process was completed. (see later pages of the document)



Yazarların Ülkeleri / Bölgeleri		Türkiye		Author's Country / Territory		Turkey	
Hakem atanması		2 hakem		Reviewer assignment		2 reviewers	
Hakemlerin Ülkeleri / Bölgeleri		Türkiye		Reviewer's Country / Territory		Turkey	
Hakem 1	İlk değerlendirme	Makale puanı	[70,1] /100	Reviewer 1	First evaluation	Article score	[70.1] /100
		Karar	Minör revizyon			Decision	Minor revision
Hakem 2	İlk değerlendirme	Makale puanı	[69,1] /100	Reviewer 2	First evaluation	Article score	[69.1] /100
		Karar	Minör revizyon			Decision	Minor revision
Hakem önerileri / Hakemlere yanıt ve revizyonlar				Reviewer suggestions / Answering reviewers and revisions			

Reviewer 1

Dear editor

This case report can be accepted for publication after the errors, examples of which are presented below, are revised:

1. Title: Entecavir induced severe **miyopathy** – myopathy
2. hepatic failure and **unfortunately** hepatocellular carcinoma -- hepatic failure and hepatocellular carcinoma
3. Keywords???
4. **comorbidies** such as cirrhosis -- **comorbidities**
5. It is **an** globally used -- **a** globally
6. **malaise and** flu symptoms -- flu **like** symptoms
7. **All of these** side effects -- **All these**
8. **conscious** and cooperative – **conscious, and cooperative**
9. entecavir-induced **secere** myopathy – **severe**
10. mitochondrial toxicity -- mitochondrial toxicity
11. many kind of side effects -- many **kinds** of side effects

Reviewer 2

This article presenting a rare drug side effect may be published after simple errors are corrected:

- a) It should be revised in terms of language. Expansions of abbreviations should be written. Drug active ingredients must be spelled correctly.
- b) There are no keywords?
- c) HBV-DNA levels -- DNA (**deoxyribonucleic acid**) levels abbreviation
- d) **CK** and **AST, ALT** levels. The examination and **EMG** -- abbreviations
- e) **clevudine** -- **clevudine**
- f) **telbuvidin** – **telbivudine**

Reviewers' suggestions were scrutinized, and typos, including the title, were revised. Added explanations of abbreviations. Keywords (Hepatitis B, Antiviral therapy, Nucleoside analog) were added.



Hakemler revizyon sonrası kabul kararı verdiği için değerlendirme süreci editör tarafından tamamlandı.

The evaluation process was completed by the editor, as the "Reviewer 1 and 2" made an acceptance decision after the revision.

iThenticate benzerlik oranı (son inceleme)	[%9]	iThenticate similarity rate (last review)	[9%]
---	--------	--	--------

was 1411 IU/L. His kidney functional tests and other routine biochemical tests were normal. HBV-DNA (deoxyribonucleic acid) levels have been measured negatively over the past two years. In line with these tests, the patient was admitted to the clinic. Among the autoimmune tests studied during his hospitalization, anti-nuclear antibody, anti-mitochondrial antibody, anti-smooth muscle antibody, and rheumatoid factor tests results were all negative. The erythrocyte sedimentation rate was normal, and the C-reactive protein level was slightly elevated. The patient's neurology consultation was obtained. In the electrophysiological study performed in the neurology myopathic pattern with normal nerve conduction. Bas examination, and biochemical tests, entecavir-induced severe entecavir treatment was discontinued. Three weeks after the kinase level was decreased to 235 IU/L. With the improve were improved significantly and the patient's exercise capacity outpatient clinic at frequent intervals until his condition sta to totally normal.

Abstract

Chronic hepatitis B virus (HBV) infection is a chronic viral illness that affects millions of people around the world and can cause serious consequences such as hepatic failure and hepatocellular carcinoma. Entecavir, a guanosine nucleoside analog (NA), is a commonly used and generally safe therapeutic agent in HBV infection. In this paper, we aimed to present a case of chronic HBV that developed severe myopathy as an extremely rare side effect after the use of entecavir. Patients receiving entecavir therapy for chronic HBV should be closely monitored for the development of myopathy as well as other known and common side effects.

Keywords: Hepatitis B, Antiviral therapy, Nucleoside analog.

Discussion

Some cases of myopathy related to the use of clevudine, telbivudine or adefovir have been reported in the literature. In this case report, a rare case of severe myopathy that developed with the use of entecavir during chronic HBV treatment was presented. The distinctive features of the case were muscle pain, loss of strength in the proximal muscles of the lower extremities, and high serum CK (creatine kinase) and AST (aspartate aminotransferase), ALT (alanine aminotransferase) levels. The physical examination and EMG (electromyography) characteristics performed in the neurology consultation were very similar to the cases with polymyositis (PM) [5]. But the absence of interstitial lung disease and/or dysphagia in our patient suggested primarily a drug-related side effect.

9%
SIMILARITY INDEX

PRIMARY SOURCES

1	www.selcukmedj.org	45 words — 4%
2	synapse.koreamed.org	26 words — 2%
3	www.xiahepublishing.com	13 words — 1%
4	www.pediatricsconsultantlive.com	11 words — 1%
5	mafiadoc.com	10 words — 1%
6	Mustafa Cesur, Fahri Bayram, Mehtap Akcil Temel, Mesut Ozkaya et al. "Thyrototoxic hypokalaemic periodic paralysis in a Turkish population: three new case reports and analysis of the case series", Clinical Endocrinology, 2008	9 words — 1%

Referanslar hariç tutulmuştur - References are excluded

Editör / Alan Editörü kararı	Kabul	Decision of Editor / Field Editor	Accept
İngilizce Dil Editörü	Öğr.Gör. Mehmet ASLAN	English Language Editor	Lect. Mehmet ASLAN
Makale kabul tarihi	06.04.2021	Article accepted date	06.04.2021
Makale yayımlanma tarihi	07.04.2021	Article published date	07.04.2021